Mariner’s NervGen Pharma NGEN Stock Holding History

Mariner’s Portfolio NGEN Stock Details NGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.8K	Hold	17,875	–	–	﹤0.01%	3442
2026 Q1	$67.4K	Buy	+17,875	New	+$77.4K	﹤0.01%	3390

Other funds holding NGEN

EAM

Empery Asset Management New York $86.5M AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

GCM

Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Mariner's NGEN Position: Q2 2026 in Review

Mariner held its NervGen Pharma (NGEN) position steady in Q2 2026 at 17,875 shares worth $36.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3442.

Mariner first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. The position peaked at $67.4K in Q1 2026. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

Mariner held 17,875 shares of NervGen Pharma worth $36.8K as of Q2 2026.
Mariner left its NervGen Pharma share count unchanged in Q2 2026.
NervGen Pharma made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3442 holding.
Mariner first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
Mariner's NervGen Pharma position peaked at $67.4K in Q1 2026.
62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.